UPDATE: BMO Capital Markets Downgrades NuVasive to Underperform, Raises PT on Multiple Positive Factors


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


In a report published Monday, BMO Capital Markets analyst Joanne K. Wuensch downgraded the rating on

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

NuVasive (NASDAQ: NUVA) from Market Perform to Underperform, but raised the price target from $18.00 to $22.00.In the report, BMO Capital Markets noted, “We are downgrading shares of NUVA to Underperform from Market Perform, given 1) the significant recovery in the stock since its 3Q12 miss (the stock is up 73% YTD), 2) a stable, but not robust spine market, and 3) a pattern over the past four years for the stock to trade up in the 1H of the year and down in the 2H (while the stock has meaningfully recovered YTD, it is just 10% higher than where it was a year ago, with a big swoon in between, versus an 18% rise in the S&P 500).”NuVasive closed on Friday at $26.70.
Posted In: Analyst ColorDowngradesAnalyst RatingsBMO Capital MarketsJoanne K. Wuensch